VWF A1 Domain Binding Polypeptides for TTP Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for thrombotic thrombocytopenia purpura (TTP) are not universally effective, as plasma transfusions require multiple exchanges over many days and do not consistently prevent blood clotting, leading to undesirable side effects and recurrence of TTP-related events.
Innovation Solution
Development of polypeptides comprising immunoglobulin single variable domains that specifically bind to the A1 domain or autoinhibitory module of von Willebrand Factor (VWF), derived from camelid antibodies, which can be administered to normalize platelet counts and reduce TTP-related deaths and thromboembolic events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plasma transfusions are used to treat TTP, then blood clotting can be prevented, but multiple exchanges over many days are required and treatment is not universally effective
Solution Approach 1:
The patent extracts the essential function of plasma therapy by using a purified monoclonal antibody fragment (caplacizumab) that specifically targets VWF A1 domain. This extraction allows the treatment to achieve the same therapeutic effect as plasma transfusions without requiring multiple exchanges over many days, thereby resolving the contradiction between treatment reliability and time loss.
Solution Approach 2:
The patent changes the parameter of treatment specificity by using a monoclonal antibody with high affinity (Kd = 1.8 nM) for VWF A1 domain. This parameter change enables the treatment to be both highly effective and rapid-acting, resolving the contradiction by achieving reliable treatment outcomes much faster than traditional plasma transfusions.
2Reliability
If plasma transfusions are used to treat TTP, then abnormal blood clotting can be addressed, but the treatment requires multiple exchanges and is not universally effective
Solution Approach 1:
The patent extracts the active therapeutic component from complex plasma transfusions, isolating a purified monoclonal antibody fragment that specifically targets VWF. This extraction simplifies the treatment protocol from multiple plasma exchanges to a single agent administration, maintaining reliable blood clotting control while reducing treatment complexity.
Solution Approach 2:
The patent creates a simplified copy of the plasma therapy mechanism using a monoclonal antibody that mimics the plasma's ability to inhibit VWF-mediated platelet aggregation. This copying approach achieves the same therapeutic effect with a simpler, more universally applicable treatment protocol.
3Object-affected harmful factors
If traditional plasma transfusions are used, then TTP treatment can be provided, but side effects occur and recurrence of TTP-related events is not prevented
Solution Approach 1:
The patent changes the parameter of treatment specificity and affinity by using a monoclonal antibody with high affinity (Kd = 1.8 nM) for VWF A1 domain. This parameter change enables the treatment to specifically target and inhibit VWF without the non-specific effects of plasma transfusions, thereby reducing side effects while improving reliability in preventing TTP recurrence through consistent platelet count normalization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively bind to the A1 domain or autoinhibitory module of VWF, reducing abnormal blood clotting, normalizing platelet counts, and decreasing the incidence of TTP-related deaths and thromboembolic events, providing a more targeted and effective treatment for TTP compared to traditional plasma transfusions.
Implementation Method 1
polypeptides comprising an immunoglobulin single variable domain that specifically binds to the A1 domain or an autoinhibitory module on the C terminal end or on the N terminal end of the A1 domain of von Willebrand Factor (VWF)
Data Source
AI summary
This disclosure relates to polypeptides comprising an immunoglobulin single variable domain that specifically binds an autoinhibitory module on the C terminal end or on the N terminal end of von Willebrand Factor (VWF) A1 domain or the von Willebrand Factor (VWF) A1 domain. In certain embodiments this disclosure relates to uses of polypeptides disclosed herein for treating or preventing bleeding or abnormal blood clotting and diseases or conditions related thereto.